With earlier communication dated September 26, 2021 intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg and 25 mg capsule (Koselugo). With regard to the same, the company now further updated that AstraZeneca Pharma India Limited has launched Koselugo in India. Selumetinib (Koselugo) is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,415 INR | +1.53% | +4.70% | -1.89% |
1st Jan change | Capi. | |
---|---|---|
-1.89% | 1.62B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ASTRAZEN Stock
- News AstraZeneca Pharma India Limited
- AstraZeneca Pharma India Limited Announces Launch of Selumetinib 10 Mg and 25 Mg Capsule